Objective: Oral sodium bicarbonate is often used to correct acid-base disturbance in patients with chronic kidney disease (CKD). However, there is little evidence on patient-level benign outcomes to support the practice.
Methods: We conducted a systematic review and meta-analysis to examine the efficacy and safety of oral sodium bicarbonate in CKD patients. A total of 1853 patients with chronic metabolic acidosis or those with low-normal serum bicarbonate (22– 24 mEq/L) were performed to compare the efficacy and safety of oral sodium bicarbonate in patients with CKD.
Results: There was a significant increase in serum bicarbonate level (MD 2.37 mEq/L; 95% CI, 1.03 to 3.72) and slowed the decline in estimated glomerular filtration rate (eGFR) (MD − 4.44 mL/min per 1.73 m², 95% CI, − 4.92 to − 3.96) compared with the control groups. The sodium bicarbonate lowered T50-time, an indicator of vascular calcification (MD − 20.74 min; 95% CI, − 49.55 to 8.08); however, there was no significant difference between the two groups. In addition, oral sodium bicarbonate dramatically reduced systolic blood pressure (MD − 2.97 mmHg; 95% CI, − 5.04 to − 0.90) and diastolic blood pressure (MD − 1.26 mmHg; 95% CI, − 2.33 to − 0.19). There were no statistically significant body weight, urine pH and mean mid-arm muscle circumference.
Conclusion: Treatment of metabolic acidosis with sodium bicarbonate may slow the decline rate of kidney function and potentially significantly improve vascular endothelial function in patients with CKD.
Prospero Registration Number: CRD42020207185.
Keywords: chronic kidney disease, metabolic acidosis, sodium bicarbonate, kidney function, cardiovascular risk